Helicobacter pylori-Eradikation: Immer? - Contra

Literatur

• 1 Armstrong D, Arnold R, Classen M. et al . RUDER - a prospective, two year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. RUDER Study Group.  Dig Dis Sci. 1994;  39 1425-1433
• 2 Bombardier C, Laine L, Reicin A. et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.  N Engl J Med. 2000;  343 1520-1528
• 3 Chan F KL, Sung J JY, Chung S CS. et al . Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.  Lancet. 1997;  350 975-979
• 4 Hawkey C J, Tulassay Z, Szczepanski L. et al . Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study.  Lancet. 1998;  352 1016-1021
• 5 Chan F K, Chung S C, Suen B Y. et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.  N Engl J Med. 2001;  344 967-973
• 6 Kuipers E J, Lundell L, Klinkenberg-Knol E C. et al . Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplicatio.  N Engl J Med. 1996;  334 1018-1022
• 7 Eissele R, Brunner G, Simon B. et al . Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.  Gastroenterology. 1997;  112 707-717
• 8 Lundell L, Miettinen P, Myrvold H E. et al . Lack of effect of acid suppression therapy on gastric atrophy.  Gastroenterology. 1999;  117 319-326
• 9 Blum A L, Talley N J, O’Morain C. et al . Lack off effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia.  N Eng J Med. 1998;  339 1875-1881
• 10 Froehlich F, Gonvers J J, Wietlisbach V. et al . Helicobacter Pylori eradication treatment does not benefit patients with nonulcer dyspepsia.  Am J Gastroenterol. 2001;  96 2329-2336
• 11 Koelz H R, Arnold R, Stolte M, Fischer M, Blum A L. the FROSCH Study Group . Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up.  Gut. 2003;  52 40-46
• 12 McColl K, Murray L, El O mar E. et al . Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.  N Engl J Med. 1998;  339 1869-1874
• 13 Talley N J, Vakil N, Ballard E D. et al . Absence of benefit of eradicating Helicobacter pylori in patient with nonulcer dyspepsia.  N Engl J Med. 1999;  341 1106-1111
• 14 Correa P, Fontham E TH, Bravo J C. et al . Chemoprevention of gastric dysplasia: randomised study.  Gastroenterology. 2000;  119 7-14
• 15 Sung J J, Lin S R, Ching J YL. et al . Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective randomised study.  Gastroenterology. 2000;  119 7-14
• 16 Sung J J, Lin S R, Leung W K. et al . Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up.  Gastroenterology. 2002;  122 S1142